10-K/A: VivoSim Labs Amends Annual Report, Details Executive Compensation and Governance Amid Going Concern Warning

VivoSim Labs, Inc. filed an amendment to its annual report to provide detailed information on executive compensation, corporate governance, and related party transactions, including a change in its Chief Financial Officer and auditor, while its auditor noted substantial doubt about the company's ability to continue as a going concern.

Summary

• Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended March 31, 2025, was filed to include previously omitted information from Part III (Items 10-14) and updated Sarbanes-Oxley Act Section 302 certifications.
• No financial statements were included or amended in this filing.
• Norman Staskey was appointed President and Chief Financial Officer on December 30, 2024, replacing Thomas Hess, who resigned on December 24, 2024, to pursue retirement.
• The company's aggregate market value of voting and non-voting common equity held by non-affiliates was $7,720,472 as of September 30, 2024.
• Outstanding shares of common stock were 2,599,797 as of July 25, 2025.
• The company's independent registered public accounting firm, Rosenberg Rich Baker Berman P.A., included an explanatory paragraph in its audit reports for fiscal years ended March 31, 2025, and 2024, regarding substantial doubt about the company's ability to continue as a going concern.
• Keith Murphy, Executive Chairman, received $726,674 in cash payments for Fiscal 2025, an approximate 10% increase due to additional hours, and was granted options valued at $428,113, including performance-based options tied to a major strategic partnership, stock price exceeding $18.36, and cumulative revenue of $1.5 million.

Sentiment

Score: 3

Explanation: The disclosure of a 'going concern' explanatory paragraph by the independent auditor for two consecutive fiscal years (2024 and 2025) is a significant negative indicator of the company's financial viability. While the filing primarily addresses governance and compensation, this financial risk overshadows other details. The failure to secure equity financing by the specified deadline for 'True-Up Options' further suggests financial challenges.

Positives

• Stockholders approved the Fiscal 2024 Say-on-Pay proposal with approximately 92% of votes in favor, indicating strong support for executive compensation practices.
• The company maintains robust corporate governance practices, including an independent Audit Committee with a financial expert, a Code of Business Conduct, and an Insider Trading Policy prohibiting hedging and pledging.
• The Board of Directors includes members with extensive experience in life sciences, biotechnology, finance, and accounting, providing diverse expertise.

Negatives

• The independent auditor's report for fiscal years ended March 31, 2025, and 2024, includes an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern.
• Current executive officers, retained through consulting firms, are not eligible for performance-based cash incentives, which could limit direct alignment with short-term operational goals.
• The company did not close an equity financing by March 31, 2025, which prevented the granting of 'True-Up Options' to the Executive Chairman, indicating a missed financial milestone.

Risks

• Substantial doubt about the company's ability to continue as a going concern, as noted by the independent registered public accounting firm.
• Reliance on consulting firms for key executive roles (Executive Chairman, CFO) means these officers are not directly eligible for performance-based cash incentives, potentially affecting motivation or alignment.
• The company's business model involves related party transactions with Viscient Biosciences, Inc., led by the Executive Chairman, which could raise potential conflicts of interest, despite a policy for Audit Committee review.

Future Outlook

The company plans to continue annual engagement with institutional stockholders to discuss executive compensation programs and feedback. The Compensation Committee will closely examine stockholder feedback and seek advice from independent compensation consultants for program design. Performance-based options for the Executive Chairman are tied to future milestones such as securing a major strategic partnership, achieving a specific stock price target ($18.36), and reaching cumulative revenue of $1.5 million from combined cell line sales, IP licensing, non-dilutive collaborations, grants, and partnerships.

Management Comments

• Our executive compensation program focuses on creating alignment between our stockholders and executive officers by including both performanceand incentive-based compensation elements.
• We plan to continue to: at least annually, reach out to institutional stockholders representing a majority of the shares held by our institutional stockholders; and invite them to engage and participate in calls to discuss our executive compensation programs, their feedback and questions and how we may best address them.
• The Compensation Committee believes that the performance goals established for incentives do not encourage excessive risk-taking or have the potential to encourage behavior that may have a material adverse effect on the Company.
• We have not timed, and do not plan to time, the disclosure of MNPI for the purpose of affecting the value of executive compensation.

Industry Context

VivoSim Labs operates in the biotechnology and medical research sector, specifically focusing on technology platforms and 3D bioprinting. The company's peer group for compensation benchmarking emphasizes companies with comparable market valuations, employee counts, and a focus on technology platforms and Phase II/III drug candidates, indicating a strategic emphasis on drug discovery and development within the life sciences industry. The related party transactions with Viscient Biosciences, also involved in 3D tissue technology and multi-omics, highlight the company's continued engagement in advanced biotech research.

Comparison to Industry Standards

• The company's executive compensation program is benchmarked against a peer group of biotechnology and medical research companies with technology platforms, an emphasis on Phase II/III drug candidates, market capitalization less than $100 million, and fewer than 50 employees.
• The peer group for Fiscal 2025 included companies such as Aligos Therapeutics, Inc., Hepion Pharmaceuticals, Inc., Scorpius Holdings, Inc., Anika Therapeutics, Inc., Hoth Therapeutics, Inc., Seelos Therapeutics, Inc., Aprea Therapeutics, Inc., Immunic Therapeutics, Inc., Soligenix, Inc., Ayala Pharmaceuticals, Imunon, Inc., Theriva Biologics, Inc., Bolt Biotherapeutics, Inc., LadRx Corp., Traws Pharma, Inc., Cumberland Pharmaceuticals, Inc., Lifecore Biomedical, and Pulmatrix, Inc.
• The company's compensation practices, including annual Say-on-Pay votes, use of an independent compensation consultant (Anderson Pay Advisors), and prohibitions on hedging/pledging, align with good compensation governance practices observed in the industry.

Management Changes

Corporate Governance

Related Party Transactions

• The company has an Intercompany Agreement with Viscient Biosciences, Inc., where Keith Murphy, the Executive Chairman and a director, serves as CEO and President.
• Under this agreement, the company incurred $118,000 in R&D consulting expenses from Viscient for the fiscal year ended March 31, 2025 (compared to $0 in FY2024).
• The company provided approximately $3,000 of histology services to Viscient for the fiscal year ended March 31, 2025 (compared to $14,000 in FY2024).
• Other directors (Messrs. Stern, Cohen, and Gobel) have invested in Viscient through a convertible promissory note but do not serve as employees, officers, or directors of Viscient.
• The company has a written Related Party Transaction Policy requiring Audit Committee approval for transactions exceeding $120,000 involving related parties.

Stakeholder Impact

• Shareholders: The 'going concern' warning from the auditor indicates significant financial risk, potentially impacting share value and long-term investment viability. The failure to secure equity financing for 'True-Up Options' also suggests challenges in capital raising.
• Management/Executives: Compensation details are transparent, with the new CFO's compensation disclosed. The Executive Chairman's compensation increased due to more hours, and his long-term incentives are tied to significant company milestones.
• Employees: The 401(k) plan with a 3.5% company match and health/dental/vision/life/disability insurance are positive benefits. The 'going concern' risk could imply future job insecurity.
• Creditors/Suppliers: The 'going concern' warning suggests increased risk for those extending credit or providing services to the company.

Next Steps

• The company plans to continue annual engagement with institutional stockholders to discuss executive compensation programs.
• The Compensation Committee will continue to evaluate and set base salaries for executives following annual performance evaluations, promotions, or changes in responsibility.
• The company expects to continue to utilize its policies for executive compensation going forward.
• Performance-based options for the Executive Chairman are contingent on future milestones, including entering a major strategic partnership, achieving a 90-day moving average stock price exceeding $18.36, and reaching cumulative revenue of $1.5 million.

Key Dates

Recommendation

The explicit 'substantial doubt about our ability to continue as a going concern' statement from the independent auditor is a critical red flag that signals severe financial distress and high risk. This fundamental concern outweighs any positive aspects of corporate governance or executive compensation structure. The failure to secure equity financing for the Executive Chairman's 'True-Up Options' further underscores capital challenges. A seasoned investor would likely view this as a strong signal to exit or avoid the stock due to the high probability of financial instability or potential bankruptcy.

Keywords

VivoSim Labs, VIVS, SEC Filing, 10-K/A, Annual Report Amendment, Executive Compensation, Corporate Governance, Biotechnology, 3D Bioprinting, Financial Reporting, Audit Committee, Going Concern, Related Party Transactions, Nasdaq